File(s) under permanent embargo
A novel metalloprotease in rat brain cleaves the amyloid precursor protein of Alzheimer's disease generating amyloidogenic fragments
journal contributionposted on 2023-05-17, 10:03 authored by Mok, SS, Evin, G, Li, QX, Smith, AI, Beyreuther, K, Masters, CL, David SmallDavid Small
The amyloid protein (AÎ² or Î²A4) is the major constituent of amyloid plaques in the Alzheimer's disease brain. AÎ² is cleaved from the amyloid precursor protein (APP) by a mechanism which is poorly understood. Cell culture studies suggest that APP may be cleaved by secretases within the late Golgi compartment. Studies performed so far have mainly used exogenous APP and synthetic peptides as substrates. For this study, a Golgi and plasma membrane-enriched fraction was isolated from rat brain and incubated at 37 Â°C at pH 7.2 to study the degradation of endogenous APP. The breakdown of APP was accompanied by the concomitant generation of AÎ²-containing C- terminal fragments, in a time-dependent fashion. The metal ion chelators EDTA and 1,10-phenanthroline inhibited this degradation. The inhibition by EDTA was reversed by 50 Î¼M Zn2+ but not by other metal ions. The protease activity was not inhibited by cysteine, serine or aspartic protease inhibitors nor was it inhibited by compounds which are inhibitors of known metalloendopeptidases and matrix metalloproteinases (cFP, phosphoramidon and TIMP-2). Our data suggest that a novel Zn2+-dependent metalloprotease activity associated with a Golgi and plasma membrane-enriched fraction can degrade endogenous APP to generate AÎ² containing C-terminal fragments. This protease may generate amyloidogenic fragments of APP which may serve as precursors for AÎ².
Department/SchoolMenzies Institute for Medical Research
PublisherAmer Chemical Soc
Place of publication1155 16Th St, Nw, Washington, USA, Dc, 20036
Rights statementCopyright © 1997 American Chemical Society